首页 | 本学科首页   官方微博 | 高级检索  
检索        

Ⅲ Ⅳ型肝门胆管癌扩大肝切除临床疗效分析*
引用本文:王冬冬,孙万亮,鲁正,吴维,马翔,吴斌全,吴华,郭婕,孙医学,张阳,崔培元.Ⅲ Ⅳ型肝门胆管癌扩大肝切除临床疗效分析*[J].中国肿瘤临床,2016,43(6):250-254.
作者姓名:王冬冬  孙万亮  鲁正  吴维  马翔  吴斌全  吴华  郭婕  孙医学  张阳  崔培元
作者单位:作者单位:①蚌埠医学院第一附属医院肝胆外科(安徽省蚌埠市233000);②超声室;③介入科
基金项目:本文课题受安徽省科技攻关项目(编号1604a0802087)资助@@@@This work was supported by the Anhui Province Science and Technology Research Project (1604a0802087)
摘    要:目的:探讨扩大肝切除对Bismuth-Corlette Ⅲ、Ⅳ型肝门胆管癌的临床疗效。方法:回顾性分析蚌埠医学院第一附属医院2008年1 月至2015年5 月61例Bismuth-Corlette Ⅲ、Ⅳ型肝门部胆管癌患者的临床资料。其中扩大肝切除组行半肝及以上肝切除和(或)联合尾状叶切除术22例;局限肝切除组行肝门区不规则肝切除术39例。结果:扩大肝切除组患者相比局限肝切除组手术时间长、术中出血量多。扩大肝切除组患者并发症发生率低于局限肝切除组患者;扩大肝切除组无围手术期死亡患者,局限肝切除组有2 例围手术期死亡患者;扩大肝切除组R 0 切除21例,R 0 切除率为95.5%(21/ 22),局限肝切除组R 0 切除20例,R 0 切除率为51.3%(20/ 39),差异具有统计学意义(P < 0.05);扩大肝切除组1、3、5 年生存率分别是77.27% 、36.36% 、13.64% ;局限肝切除组1、3、5 年生存率分别是69.23% 、20.51% 、1.64% ,差异具有统计学意义(P < 0.05)。 结论:Bismuth-Corlette Ⅲ、Ⅳ型肝门部胆管癌扩大肝切除可以有效提高患者的R 0 切除率和生存率,改善患者的预后。 

关 键 词:肝门胆管癌?    手术治疗?    扩大肝切除?    局限肝切除?    疗效
收稿时间:2015-11-09

Clinical efficacy of extended hepatectomy for types III and IV hilar cholangiocarcinoma
Institution:1Department of Hepatobiliary Surgery, First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China;
Abstract:Objective:To investigate the clinical efficacy of extended hepatectomy for hilar cholangiocarcinoma (HCCA) of Bismuth-Cor-lette typesⅢandⅣ(the longitudinal invasion degree along the biliary system is the main criteria). Methods:The clinical data of 61 patients with HCCA of Bismuth-Corlette types III and IV admitted in the Department of Hepatobiliary Surgery of the First Affiliated Hos-pital of Bengbu Medical College from January 2008 to May 2015 were analyzed retrospectively. Among the 61 cases, 22 underwent hepatectomy with half or over half of the liver removed or hepatic caudate lobectomy (regarded as the extended hepatectomy group), whereas 39 cases underwent irregular hepatectomy on the hepatic hilar region (regarded as the limited hepatectomy group). Results:Compared with those in the limited hepatectomy group, the patients in the extended hepatectomy group underwent longer duration of operation and experienced more bleeding during the procedure. The complication incidence rate for the extended hepatectomy group was lower than that for the limited hepatectomy group. No patient died during the perioperative period in the extended hepa-tectomy group, whereas two patients died in the limited hepatectomy group. Moreover, R0 resection was performed on 21 cases in the extended hepatectomy group, with a resection rate of (21/22) 95.5%, and on 20 cases in the limited hepatectomy group (P<0.05), with a resection rate of (20/39) 51.3%. Actuarial 1-, 3-, and 5-year survival rates were 77.27%, 36.36%, and 13.64%, respectively, in the extended hepatectomy group, and 69.23%, 20.51%, and 1.64%, respectively, in the limited hepatectomy group (P<0.05). Conclusion:Extended hepatectomy for patients with HCCA of Bismuth-Corlette typesⅢandⅣcould effectively increase the resection rates of R0 and the survival rate. Meanwhile, the prognosis of patients could be improved.
Keywords:hilar cholangiocarcinoma  surgical therapy  extended hepatectomy  limited hepatectomy  curative effect
本文献已被 万方数据 等数据库收录!
点击此处可从《中国肿瘤临床》浏览原始摘要信息
点击此处可从《中国肿瘤临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号